Trending Now
Myovant Sciences (NYSE:MYOV) Receives FDA Approval For Oral ORGOVYX™ In Advanced...
Myovant Sciences (NYSE:MYOV) has announced that the US FDA has granted ORGOVYX™ (relugolix) approval for the treatment of advanced prostate cancer patients....
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Recursion (NASDAQ: RXRX) Expands Strategic Partnership With BAYER On Fibrotic Diseases
Recursion (NASDAQ: RXRX) has expanded its current strategic partnership with Bayer AG in Fibrosis. The expanded partnership includes Recursion's robust inferential search abilities based...
MAKE IT MODERN
LATEST REVIEWS
Metacrine Inc. (NASDAQ: MTCR) On Track to Begin Second Phase Clinical...
Metacrine Inc. (NASDAQ: MTCR) has announced that it is on track to commence a second phase clinical study in ulcerative colitis. In addition, the...
MAKE IT MODERN
PERFORMANCE TRAINING
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Reports Topline Results Of AT-GAA In Phase 3, 52-Week Clinical...
Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted topline results in treating LOPD (Late-onset Pompe disease) using its AT-GAA in phase 3, 52-week clinical trial. The US...
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) Meets Its Primary and Secondary Endpoint in the Study...
Tarsus Pharmaceuticals Inc's (NASDAQ: TARS) treatment, TP-03, has met primary and secondary endpoints in the company’s Phase III study. The company also found that...
BioNTech Se (NASDAQ:BNTX) And EIB Sign €100 Million Financing Agreement for COVID-19 Vaccine Development
BioNTech Se (NASDAQ:BNTX) and the European Investment Banks (EIB) have finalized a debt financing agreement of €100 million to support the development of the...
Oncolytics Bioetch Inc. (NASDAQ: ONCY) Presents Enrolment Updates of Phase 1/2 GOBLET Study at...
Oncolytics Bioetch Inc. (NASDAQ: ONCY) has presented a recruitment update in the Phase 1/2 GOBLET trial in a poster at the 2022 American Society...
Intellia Therapeutics Inc. (NASDAQ: NTLA) Receives MHRA Approval To Amend Phase I NTLA 2001...
Intellia Therapeutics Inc. (NASDAQ: NTLA) has announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has given approval for amendment of protocol...
MAKE IT MODERN
